87 related articles for article (PubMed ID: 26178438)
41. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
42. Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity.
Vail DM
Top Companion Anim Med; 2009 Aug; 24(3):122-9. PubMed ID: 19732730
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
Silver M; Rusk A; Phillips B; Beck E; Jankowski M; Philibert J; Hahn K; Hershey E; McKeegan E; Bauch J; Krivoshik A; Khanna C
J Vet Intern Med; 2012; 26(2):349-54. PubMed ID: 22369215
[TBL] [Abstract][Full Text] [Related]
44. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs.
Giorgi M; Meizler A; Mills PC
Vet J; 2012 Dec; 194(3):309-13. PubMed ID: 22771148
[TBL] [Abstract][Full Text] [Related]
46. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
47. Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy.
Boss MK; Dewhirst MW; Sampaio RS; Bennett A; Tovmasyan A; Berman KG; Beaven AW; Rizzieri DA; Batinic-Haberle I; Hauck ML; Spasojevic I
Cancer Chemother Pharmacol; 2017 Aug; 80(2):421-431. PubMed ID: 28685347
[TBL] [Abstract][Full Text] [Related]
48. Serial evaluation of neutrophil function in tumour-bearing dogs undergoing chemotherapy.
LeBlanc AK; LeBlanc CJ; Rohrbach BW; Kania SA
Vet Comp Oncol; 2015 Mar; 13(1):20-7. PubMed ID: 23331512
[TBL] [Abstract][Full Text] [Related]
49. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans.
Akabane T; Tanaka K; Irie M; Terashita S; Teramura T
Xenobiotica; 2011 May; 41(5):372-84. PubMed ID: 21385103
[TBL] [Abstract][Full Text] [Related]
50. Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors.
Hosoya K; Couto CG; London CA; Kisseberth WC; Phelps MA; Dalton JT
J Am Anim Hosp Assoc; 2014; 50(6):390-5. PubMed ID: 25251432
[TBL] [Abstract][Full Text] [Related]
51. Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Politi PM; Xie F; Dahut W; Ford H; Kelley JA; Bastian A; Setser A; Allegra CJ; Chen AP; Hamilton JM
Cancer Chemother Pharmacol; 1995; 36(6):513-23. PubMed ID: 7554044
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of buprenorphine following intravenous and oral transmucosal administration in dogs.
Abbo LA; Ko JC; Maxwell LK; Galinsky RE; Moody DE; Johnson BM; Fang WB
Vet Ther; 2008; 9(2):83-93. PubMed ID: 18597246
[TBL] [Abstract][Full Text] [Related]
53. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of oral rufinamide in dogs.
Wright HM; Chen AV; Martinez SE; Davies NM
J Vet Pharmacol Ther; 2012 Dec; 35(6):529-33. PubMed ID: 22132708
[TBL] [Abstract][Full Text] [Related]
55. Safety and pharmacokinetics of thalidomide in tumor-bearing dogs.
Matsuyama F; Fujita Y; Fukazawa E; Kobayashi T
J Vet Med Sci; 2023 Dec; 85(12):1261-1268. PubMed ID: 37813647
[TBL] [Abstract][Full Text] [Related]
56. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Sessa C; Zucchetti M; Ghielmini M; Bauer J; D'Incalci M; de Jong J; Naegele H; Rossi S; Pacciarini MA; Domenigoni L; Cavalli F
Cancer Chemother Pharmacol; 1999; 44(5):403-10. PubMed ID: 10501914
[TBL] [Abstract][Full Text] [Related]
57. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.
Matsuyama F; Harada K; Fukazawa E; Ichimata M; Nakano Y; Kobayashi T
J Vet Intern Med; 2022 Jul; 36(4):1409-1415. PubMed ID: 35524687
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs.
Norkus C; Rankin D; KuKanich B
Vet Anaesth Analg; 2015 Nov; 42(6):580-9. PubMed ID: 25683584
[TBL] [Abstract][Full Text] [Related]
60. Tolerability of metronomic administration of lomustine in dogs with cancer.
Tripp CD; Fidel J; Anderson CL; Patrick M; Pratt C; Sellon R; Bryan JN
J Vet Intern Med; 2011; 25(2):278-84. PubMed ID: 21314727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
